Minerva Neurosciences reports Q2 2026 results, update on roluperidone Phase 3 trial
Minerva Neurosciences provided an update on the confirmatory Phase 3 clinical trial of roluperidone for negative symptoms of schizophrenia, expecting topline efficacy data in the second half of 2027. The company announced the addition of experts to its Scientific Advisory Board.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day